Daniel  Faga net worth and biography

Daniel Faga Biography and Net Worth

Presently, Daniel R. Faga is Executive VP, Chief Operating & Financial Officer at Mirati Therapeutics, Inc. In the past he held the position of Managing Director at Centerview Partners LLC and Chief Business Officer at Spark Therapeutics, Inc. He received an undergraduate degree from Cornell University and an MBA from The Wharton School of the University of Pennsylvania.

What is Daniel Faga's net worth?

The estimated net worth of Daniel Faga is at least $43.97 million as of March 25th, 2024. Mr. Faga owns 749,087 shares of Mirati Therapeutics stock worth more than $43,971,407 as of November 7th. This net worth estimate does not reflect any other investments that Mr. Faga may own. Learn More about Daniel Faga's net worth.

How do I contact Daniel Faga?

The corporate mailing address for Mr. Faga and other Mirati Therapeutics executives is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Mirati Therapeutics can also be reached via phone at (858) 332-3410 and via email at [email protected]. Learn More on Daniel Faga's contact information.

Has Daniel Faga been buying or selling shares of Mirati Therapeutics?

Daniel Faga has not been actively trading shares of Mirati Therapeutics over the course of the past ninety days. Most recently, Daniel Faga sold 1,340 shares of the business's stock in a transaction on Tuesday, February 2nd. The shares were sold at an average price of $194.38, for a transaction totalling $260,469.20. Learn More on Daniel Faga's trading history.

Who are Mirati Therapeutics' active insiders?

Mirati Therapeutics' insider roster includes Charles Baum (CEO), Bruce Carter (Director), Julie Cherrington (Director), Jamie Christensen (EVP), Daniel Faga (COO), Henry Fuchs (Director), Benjamin Hickey (EVP), Craig Johnson (Director), and Vickie Reed (CAO). Learn More on Mirati Therapeutics' active insiders.

Are insiders buying or selling shares of Mirati Therapeutics?

In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 7,438 shares worth more than $433,243.25. The most recent insider tranaction occured on January, 16th when EVP Benjamin Hickey sold 1,597 shares worth more than $94,254.94. Insiders at Mirati Therapeutics own 3.3% of the company. Learn More about insider trades at Mirati Therapeutics.

Information on this page was last updated on 1/16/2024.

Daniel Faga Insider Trading History at Mirati Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/2/2021Sell1,340$194.38$260,469.20
1/7/2021Sell2,625$216.33$567,866.2526,228View SEC Filing Icon  
See Full Table

Daniel Faga Buying and Selling Activity at Mirati Therapeutics

This chart shows Daniel Faga's buying and selling at Mirati Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mirati Therapeutics Company Overview

Mirati Therapeutics logo
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $58.70
Low: $58.70
High: $58.70

50 Day Range

MA: $58.82
Low: $58.70
High: $59.28

2 Week Range

Now: $58.70
Low: $27.30
High: $64.41

Volume

N/A

Average Volume

2,758,857 shs

Market Capitalization

$4.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77